

Intercytex

[View the current Intercytex Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24741-Intercytex.html)

(<http://www.bioportfolio.com/biocorporate/24741-Intercytex.html>)

Contact Details:

St John's Innovation Centre
Cowley Road
Cambridge
Cambridgeshire
CB4 0WS
United Kingdom

Tel: 44 (0)1223 421962
Fax: 44 (0)1223 421961
Email: mail@intercytex.com

Intercytex is an emerging healthcare company developing and commercialising cell therapy products for the woundcare and aesthetic medicine markets. Intercytex is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has four products in development.

ICX-PRO, designed actively to stimulate repair in chronic wounds - in Phase III trials

ICX-SKN, being developed as a durable and robust skin replacement - due to start Phase I trials during 2006

ICX-RHY, a facial rejuvenation product - in Phase I trials

ICX-TRC, a hair regeneration product - about to commence Phase II trials

Intercytex commenced operations in 2000 and currently employs around 70 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility plus research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.

Intercytex' shares were admitted for trading on the Alternative Investment Market of the London Stock Exchange on 1 February 2006 under the ticker symbol ICX.L.

Recent Publications by Intercytex:



- [Hair follicle neogenesis induced by cultured human scalp dermal papilla cells.](#)
*AIM: To develop a method by which human hair follicle dermal papilla (DP)...*19th September, 2009
Intercytex Ltd, 175E New Boston Street, Woburn, MA 01801, USA.- Regen Med. 2009 Sep;4(5):667-76. ([DOI Direct Link](#))
- [Integration and persistence of an investigational human living skin equivalent \(ICX-SKN\) in human surgical wounds.](#)
*AIM: To present the first human clinical data on an investigational living...*2nd June, 2009
Intercytex Ltd, Innovation House, Manchester, UK.- Regen Med. 2007 Jul;2(4):363-70. ([DOI Direct Link](#))

-)
- [Tissue engineering and cell-populated collagen matrices.](#)
*Tissue engineering seeks to produce living, three-dimensional cellular...*28th April, 2009
Intercytex Ltd,- Methods Mol Biol. 2009;522:363-70. ([DOI Direct Link](#))
 - [Hair morphogenesis in vitro: formation of hair structures suitable for implantation.](#)
*AIM: To develop a construct through which implanted follicular cells will...*15th November, 2008
Intercytex, Innovation House, Crewe Road, Manchester, M23 9QR, UK.- Regen Med. 2008
Sep;3(5):683-92. ([DOI Direct Link](#))
 - [A graft model for hair development.](#)
*Follicular cell implantation (FCI) is an experimental cell therapy for the...*22nd July, 2008
Intercytex Ltd, 175-E New Boston Street, Woburn, MA, USA.- Exp Dermatol. 2008 Jun;17(6):512-8.
Epub 2007 Dec 7. ([DOI Direct Link](#))
 - [Development and manufacture of an investigational human living dermal equivalent \(ICX-SKN\).](#)
*AIM: To design and manufacture an investigational living skin graft...*30th January, 2008
Intercytex Ltd., Innovation House, Crewe Road, Manchester M23 9QR, UK.- Regen Med. 2007
Nov;2(6):903-18. ([DOI Direct Link](#))
 - [History of regenerative medicine: looking backwards to move forwards.](#)
*If the song by the international popstar Sting is to be relied upon,...*26th May, 2007
Intercytex Group Plc, Innovation House, Manchester, UK.- Regen Med. 2006 Sep;1(5):653-69. ([DOI Direct Link](#))
 - [Preservation of embryonic kidneys for transplantation.](#)
*BACKGROUND: Long-term storage of embryonic kidneys is crucial for the...*29th October, 2005
- Transplant Proc. 2005 Jan-Feb;37(1):280-4. ([DOI Direct Link](#))
 - [Transplantation of metanephroi to sites within the abdominal cavity.](#)
*A novel approach to circumventing the shortage in transplantable donor...*29th October, 2005
Intercytex Ltd, Manchester, UK.- Transplant Proc. 2005 Jan-Feb;37(1):194-7. ([DOI Direct Link](#))
 - [Reprogramming in inter-species embryonal carcinoma-somatic cell hybrids induces expression of pluripotency and differentiation markers.](#)
*Somatic cell reprogramming holds great promise for the development of...*28th July, 2004
INTERCYTEX Ltd., Manchester, United Kingdom.- Cloning Stem Cells. 2003;5(4):339-54. ([DOI Direct Link](#))

Press Releases on Intercytex:

[Reportlinker Adds Global Stem Cell and Advanced Technologies Market](#)

10th November, 2009 Reportlinker

-- Stem Cell Applications (regenerative medicine - neurological disorders, orthopedics, cancer, hematological disorders, myocardial infarction and cardiovascular diseases,

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

